



Sample Information

Patient Name: 邱美惠
Gender: Female
ID No.: J220743436
History No.: 46704534
Age: 52

Ordering Doctor: DOC1885G 楊慕華
Ordering REQ.: D5NH1E6
Signing in Date: 2021/01/27

Path No.: S110-98127
MP No.: F21007
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S110-90132A
Percentage of tumor cells: 80%
Note:

Sample Cancer Type: Head and Neck Cancer

Table of Contents	Page
Variant Details	2
Biomarker Descriptions	2
Relevant Therapy Summary	3
Relevant Therapy Details	4
Clinical Trials Summary	16
Alert Details	17

Report Highlights

1 Relevant Biomarkers
 3 Therapies Available
 10 Clinical Trials

Relevant Head and Neck Cancer Variants

Gene	Finding
ERBB2	Not detected
NTRK1	Not detected
NTRK2	Not detected
NTRK3	ETV6-NTRK3 fusion

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	ETV6-NTRK3 fusion ETS variant 6 - neurotrophic receptor tyrosine kinase 3	entrectinib ^{1,2} larotrectinib ¹	entrectinib larotrectinib TRK inhibitor	10

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
JAK1	p.(=)	c.2199A>G	.	chr1:65310489	48.19%	NM_002227.3	synonymous	1994
ALK	p.(D1529E)	c.4587C>G	.	chr2:29416366	99.95%	NM_004304.4	missense	1996
ALK	p.(I1461V)	c.4381A>G	.	chr2:29416572	99.95%	NM_004304.4	missense	1999
ALK	p.(=)	c.3375C>A	.	chr2:29445458	99.95%	NM_004304.4	synonymous	1995
FGFR3	p.(=)	c.1953G>A	.	chr4:1807894	99.80%	NM_000142.4	synonymous	1995
PDGFRA	p.(=)	c.1701A>G	.	chr4:55141055	99.75%	NM_006206.5	synonymous	1998
FGFR4	p.(P136L)	c.407C>T	.	chr5:176517797	99.05%	NM_213647.2	missense	1999
RET	p.(=)	c.2307G>T	.	chr10:43613843	49.57%	NM_020975.4	synonymous	1993

Gene Fusions (RNA)

Genes	Variant ID	Locus	Read Count
ETV6-NTRK3	ETV6-NTRK3.E4N15.COSF823.1	chr12:12006495 - chr15:88483984	498
ETV6-NTRK3	ETV6-NTRK3.E5N15.COSF571.1	chr12:12022903 - chr15:88483984	131410

Biomarker Descriptions

ETV6 (ETS variant 6)

Background: The ETV6 gene encodes the E twenty-six (ETS) variant 1 transcription factor. ETV6 contains an N-terminal pointed (PNT) domain responsible for protein-protein interactions and a C-terminal ETS domain involved in DNA binding¹. ETV6 plays a critical role in embryonic development as well as hematopoiesis and is the target of chromosomal rearrangement and missense mutations in hematological malignancies as well as solid tumors^{2,3}. Hereditary mutations in ETV6 are associated with a predisposition to hematological cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS)^{4,5,6}.

Alterations and prevalence: ETV6 translocations are prevalent in hematological malignancies and have been observed with numerous fusion partners⁷. The most recurrent translocation is t(12;21)(q34;q11) which results in ETV6-RUNX1 fusion and is observed in 20-25% childhood acute lymphoblastic leukemia (ALL)^{7,8,9}. ETV6-RUNX1 fusions are also observed in adult ALL (2%)^{8,9}. The t(5;12)(q33;p13) translocation which results in the ETV6-PDGFRB fusion is recurrent in chronic myelomonocytic leukemia (CMML)^{7,10}. Other ETV6 fusions including ETV6-PDGFRB, ETV6-NTRK2, ETV6-NTRK3, and ETV6-ABL1 are reported in hematological malignancies as well as solid tumors^{3,7,11}. ETV6 fusions involving a receptor tyrosine kinase (RTK) fusion partner retains the ETV6 PNT domain and the tyrosine kinase domain of the RTK, leading to constitutive kinase activation^{7,11}. Mutations in ETV6 are primarily missense, nonsense, or frameshift and are observed in about 1-5% of select myeloid malignancies and solid tumors, including chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), MDS, AML, ALL, melanoma, lung, bladder, stomach, colorectal, and uterine cancers^{1,12,13}. ETV6 mutations occur in the PNT and ETS domain of ETV6 and may impair ETV6 oligomerization or DNA-binding, respectively¹.

Potential relevance: ETV6-NTRK3 fusions are used as an ancillary diagnostic marker in congenital/infantile fibrosarcoma¹⁴. Nonsense or frameshift mutations in ETV6 are independently associated with poor prognosis in MDS⁶. However, ETV6-RUNX1 fusions are associated with favorable outcomes in ALL and good risk in B-cell ALL (B-ALL)⁹. ETV6 fusions that partner with a RTKs demonstrate response to various tyrosine kinase inhibitors such as imatinib, nilotinib, and entrectinib. Specifically, individual case reports of an ETV6-PDGFRB fusion chronic eosinophilic leukemia patient and an ETV6-PDGFRB fusion CMML patient treated with imatinib demonstrated complete cytogenetic response (CCyR) and complete hematological responses, respectively^{15,16}. Additionally, an ETV6-ABL1 fusion Ph-negative CML patient treated with nilotinib demonstrated CCyR and major molecular response (MMR) at 22

Biomarker Descriptions (continued)

months from diagnosis¹⁷. In another case report, an ETV6-NTRK3 fusion mammary analogue secretory carcinoma (MASC) patient demonstrated partial response to entrectinib with 89% reduction in tumor burden¹⁸.

NTRK3 (neurotrophic receptor tyrosine kinase 3)

Background: The NTRK genes encode a family of neurotrophic receptor tyrosine kinases that function as receptors for nerve growth factors. NTRKs are activated by different neurotrophins and are important for the development of the nervous system¹⁹. The NTRK1,2,3 proteins are also known as tropomyosin related kinases (TrkA,B,C) because NTRK1 was originally discovered as part of a chimeric fusion gene with tropomyosin-3 isolated from a human colon carcinoma cell line²⁰. NTRKs are the target of recurrent chromosomal rearrangements that generate fusion proteins containing the intact tyrosine kinase domain combined with numerous fusion partner genes^{21,22}. NTRK fusion kinases are constitutively active and lead to increased RAS/RAF/MEK/ERK, PI3K/AKT/MTOR, or PLCγ/PKC pathway signaling and can promote cell growth and proliferation^{21,23}.

Alterations and prevalence: NTRK fusions are infrequently observed in diverse cancer types including glioma, glioblastoma, lung adenocarcinoma, colorectal carcinoma, thyroid cancer, and sarcoma^{13,21,24,25,26}. In certain cancer subtypes, including infantile fibrosarcoma, papillary thyroid carcinoma, and secretory carcinoma of the breast or salivary gland, NTRK fusions are more prevalent^{21,27,28,29}.

Potential relevance: The first-generation selective tropomyosin receptor kinase (TRK) inhibitor, larotrectinib³⁰, is approved (2018) for the treatment of patients with any solid tumors harboring NTRK gene fusions and is the first approved small molecule inhibitor with tissue agnostic indication. Entrectinib³¹ is another first-generation TRK inhibitor approved (2019) for NTRK fusion-positive solid tumors as well as ROS1-positive non-small cell lung cancer (NSCLC). However, acquired resistance to first-generation NTRK inhibition is often mediated by the acquisition of solvent-front and gatekeeper mutations in the kinase domain³². Consequently, the second generation TRK inhibitor, repotrectinib³³, was granted fast-track designation by the FDA (2020) for the treatment of patients with advanced solid tumors and an NTRK gene fusion that have progressed following treatment with at least one prior line of chemotherapy and prior TRK inhibitor treatment.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

ETV6-NTRK3 fusion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
entrectinib	●	◐	●	×	● (II)
larotrectinib	●	◐	×	×	● (II)
TRK inhibitor	×	×	×	○	×
cabozantinib	×	×	×	×	● (II)
temsirolimus	×	×	×	×	● (II)
repotrectinib	×	×	×	×	● (I/II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2020-11-18. For the most up-to-date information, search www.fda.gov.

ETV6-NTRK3 fusion

● entrectinib

Cancer type: Solid Tumor

Label as of: 2019-08-15

Variant class: NTRK fusion

Indications and usage:

ROZLYTREK® is a kinase inhibitor indicated for the treatment of:

- Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
- Adult and pediatric patients 12 years of age and older with solid tumors that:
 - have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
 - are metastatic or where surgical resection is likely to result in severe morbidity, and
 - have progressed following treatment or have no satisfactory alternative therapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf

● larotrectinib

Cancer type: Solid Tumor

Label as of: 2018-11-26

Variant class: NTRK fusion

Indications and usage:

VITRAKVI® is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf

Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2020-11-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ETV6-NTRK3 fusion

● entrectinib

Cancer type: Solid Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Tumor agnostic; Brain metastases; See the appropriate NCCN treatment guidelines for systemic therapy recommendations for newly diagnosed brain metastases (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2020]

● entrectinib

Cancer type: Head and Neck Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Unresectable, or Metastatic Salivary Gland Tumors; PS 0-3 (Not Specified) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 2.2020]

● larotrectinib

Cancer type: Solid Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Tumor agnostic; Brain metastases; See the appropriate NCCN treatment guidelines for systemic therapy recommendations for newly diagnosed brain metastases (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2020]

● larotrectinib

Cancer type: Head and Neck Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Unresectable, or Metastatic Salivary Gland Tumors; PS 0-3 (Not Specified) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 2.2020]

ETV6-NTRK3 fusion (continued)**○ entrectinib****Cancer type:** Breast Cancer**Variant class:** NTRK fusion**NCCN Recommendation category:** 2A**Population segment (Line of therapy):**

- Recurrent or Stage IV Invasive Breast Cancer (Not specified) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 6.2020]**○ entrectinib****Cancer type:** Colorectal Cancer**Variant class:** NTRK fusion**NCCN Recommendation category:** 2A**Population segment (Line of therapy):**

- Metastatic Colorectal Cancer (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]**○ entrectinib****Cancer type:** Melanoma**Variant class:** NTRK fusion**NCCN Recommendation category:** 2A**Population segment (Line of therapy):**

- Metastatic or Unresectable Cutaneous Melanoma; Progression or maximum clinical benefit from BRAF targeted therapy (Second-line or subsequent therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]**○ entrectinib****Cancer type:** Esophageal Cancer,
Gastroesophageal Junction Adenocarcinoma**Variant class:** NTRK fusion**NCCN Recommendation category:** 2A**Population segment (Line of therapy):**

- Unresectable Locally Advanced, Recurrent or Metastatic Disease; Local therapy is not indicated (Second-line or subsequent therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 4.2020]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Gastric Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Locally Advanced, Recurrent or Metastatic Disease; Local therapy is not indicated (Second-line or subsequent therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 3.2020]

○ entrectinib

Cancer type: Gastrointestinal Stromal Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Gastrointestinal Stromal Tumor; Unresectable with significant morbidity; Disease progression (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Gastrointestinal Stromal Tumor [Version 1.2021]

○ entrectinib

Cancer type: Cholangiocarcinoma, Liver Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Gallbladder Cancer, Intra/Extrahepatic Cholangiocarcinoma; Unresectable or metastatic disease (Primary treatment) (Useful in Certain Circumstances)
- Gallbladder Cancer, Intra/Extrahepatic Cholangiocarcinoma; Disease progression; Dependent on clinical factors including previous treatment regimen/agent and extent of liver dysfunction (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 5.2020]

○ entrectinib

Cancer type: Liver Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Hepatocellular Carcinoma (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 5.2020]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease; Discovered prior to first-line systemic therapy (First-line therapy) (Preferred)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease; Discovered during first-line systemic therapy or disease progression (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

○ entrectinib

Cancer type: Ovarian Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer; Platinum-Sensitive or Resistant (Recurrence therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2020]

○ entrectinib

Cancer type: Colorectal Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic Colorectal Cancer (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]

○ entrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Soft Tissue Sarcoma Subtypes with Non-Specific Histologies, appropriate General Soft Tissue Sarcoma or Pleomorphic Rhabdomyosarcoma; Advanced/Metastatic disease; Not intended for adjuvant therapy of nonmetastatic disease (First-line therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 1.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Thyroid Gland Anaplastic Carcinoma **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Anaplastic Carcinoma; Metastatic (Not specified) (Preferred)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

○ entrectinib

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; Unresectable locoregional recurrent/persistent disease not amenable to RAI therapy (Not specified)
- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; CNS or soft tissue or bone metastases not amenable to RAI therapy (Not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

○ larotrectinib

Cancer type: Breast Cancer **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent or Stage IV Invasive Breast Cancer (Not specified) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 6.2020]

○ larotrectinib

Cancer type: Colorectal Cancer **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic Colorectal Cancer (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Melanoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; Progression or maximum clinical benefit from BRAF targeted therapy (Second-line or subsequent therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

○ larotrectinib

Cancer type: Esophageal Cancer,
Gastroesophageal Junction Adenocarcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Locally Advanced, Recurrent or Metastatic Disease; Local therapy is not indicated (Second-line or subsequent therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 4.2020]

○ larotrectinib

Cancer type: Gastric Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Locally Advanced, Recurrent or Metastatic Disease; Local therapy is not indicated (Second-line or subsequent therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 3.2020]

○ larotrectinib

Cancer type: Gastrointestinal Stromal Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Gastrointestinal Stromal Tumor; Unresectable with significant morbidity; Disease progression (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Gastrointestinal Stromal Tumor [Version 1.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Cholangiocarcinoma, Liver Cancer Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Gallbladder Cancer, Intra/Extrahepatic Cholangiocarcinoma; Unresectable or metastatic disease (Primary treatment) (Useful in Certain Circumstances)
- Gallbladder Cancer, Intra/Extrahepatic Cholangiocarcinoma; Disease progression; Dependent on clinical factors including previous treatment regimen/agent and extent of liver dysfunction (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 5.2020]

○ larotrectinib

Cancer type: Liver Cancer Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Hepatocellular Carcinoma (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 5.2020]

○ larotrectinib

Cancer type: Non-Small Cell Lung Cancer Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease; Discovered prior to first-line systemic therapy (First-line therapy) (Preferred)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease; Discovered during first-line systemic therapy or disease progression (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

○ larotrectinib

Cancer type: Ovarian Cancer Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer; Platinum-Sensitive or Resistant (Recurrence therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2020]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Pancreatic Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic Pancreatic Adenocarcinoma; Poor performance status (First-line therapy) (Useful in Certain Circumstances)
- Locally Advanced, Metastatic, or Recurrent Pancreatic Adenocarcinoma; Good or Poor performance status (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 1.2021]

○ larotrectinib

Cancer type: Colorectal Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic Colorectal Cancer (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]

○ larotrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Soft Tissue Sarcoma Subtypes with Non-Specific Histologies, appropriate for General Soft Tissue Sarcoma; Advanced/Metastatic disease; Not intended for preoperative or adjuvant therapy of nonmetastatic disease; Not recommended for Angiosarcoma or Pleomorphic Rhabdomyosarcoma (First-line therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 1.2021]

○ larotrectinib

Cancer type: Thyroid Gland Anaplastic Carcinoma Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Anaplastic Carcinoma; Metastatic (Not specified) (Preferred)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; Unresectable locoregional recurrent/persistent disease not amenable to RAI therapy (Not specified)
- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; CNS or soft tissue or bone metastases not amenable to RAI therapy (Not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

○ entrectinib

Cancer type: Cervical Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent or Metastatic Cervical Cancer (Second-line therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]

○ entrectinib

Cancer type: Pancreatic Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Metastatic Pancreatic Adenocarcinoma; Poor performance status (First-line therapy) (Useful in Certain Circumstances)
- Locally Advanced, Metastatic, or Recurrent Pancreatic Adenocarcinoma; Good or Poor performance status (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 1.2021]

○ entrectinib

Cancer type: Endometrial Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Advanced or Recurrent Endometrial Carcinoma (Not specified) (Useful in Certain Circumstances)
- Recurrent or Metastatic Uterine Sarcoma; Progression on prior cytotoxic chemotherapy (Second-line therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 1.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Cervical Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent or Metastatic Cervical Cancer (Second-line therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]

○ larotrectinib

Cancer type: Endometrial Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Advanced or Recurrent Endometrial Carcinoma (Not specified) (Useful in Certain Circumstances)
- Recurrent or Metastatic Uterine Sarcoma; Progression on prior cytotoxic chemotherapy (Second-line therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 1.2021]

Current EMA Information

☒ In this cancer type ☐ In other cancer type ☐ In this cancer type and other cancer types

EMA information is current as of 2020-11-18. For the most up-to-date information, search www.ema.europa.eu/ema.

ETV6-NTRK3 fusion

☒ entrectinib

Cancer type: Solid Tumor

Label as of: 2020-10-27

Variant class: NTRK fusion

Reference:

https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf

Current ESMO Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

ESMO information is current as of 2020-11-02. For the most up-to-date information, search www.esmo.org.

ETV6-NTRK3 fusion

☐ TRK inhibitor

Cancer type: Breast Cancer

Variant class: NTRK fusion

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):

- Advanced Breast Cancer (Not specified)

Reference: ESMO Clinical Practice Guidelines - ESMO-ESO-ESMO Advanced Breast Cancer [Annals of Oncology (2020), doi: <https://doi.org/10.1016/j.annonc.2020.09.010> (ABC 5)]




Clinical Trials Summary

ETV6-NTRK3 fusion

NCT ID	Title	Phase
NCT02576431	A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	II
NCT02568267	An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Studies of Tumor Alterations Responsive to Targeting Receptor Kinases (STARTRK-2)	II
NCT02465060	Molecular Analysis for Therapy Choice (MATCH).	II
NCT03155620	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	II
NCT03213704	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions	II
NCT03834961	Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias	II
NCT02637687	A Phase I/II Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	I/II
NCT03093116	A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	I/II
NCT04116541	MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.	II
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial	II

Alerts Informed By Public Data Sources

Current NCCN Information

 Contraindicated  Not recommended  Resistance

NCCN information is current as of 2020-11-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ETV6-NTRK3 fusion

larotrectinib

Cancer type: Angiosarcoma

Variant class: NTRK fusion

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Not recommended for angiosarcoma or pleomorphic rhabdomyosarcoma."

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 1.2021]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Wang et al. ETV6 mutation in a cohort of 970 patients with hematologic malignancies. *Haematologica*. 2014 Oct;99(10):e176-8. PMID: 24997145
2. Wang et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. *Genes Dev*. 1998 Aug 1;12(15):2392-402. PMID: 9694803
3. Huret et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. *Nucleic Acids Res*. 2013 Jan;41(Database issue):D920-4. PMID: 23161685
4. Feurstein et al. Germline ETV6 mutations and predisposition to hematological malignancies. *Int. J. Hematol*. 2017 Aug;106(2):189-195. PMID: 28555414
5. Melazzini et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. *Haematologica*. 2016 Nov;101(11):1333-1342. PMID: 27365488
6. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 1.2021]
7. De et al. ETV6 fusion genes in hematological malignancies: a review. *Leuk. Res*. 2012 Aug;36(8):945-61. PMID: 22578774
8. Pui et al. Acute lymphoblastic leukemia. *N. Engl. J. Med*. 2004 Apr 8;350(15):1535-48. PMID: 15071128
9. NCCN Guidelines® - Acute Lymphoblastic Leukemia [Version 2.2019]. 2019 May 15
10. Golub et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell*. 1994 Apr 22;77(2):307-16. PMID: 8168137
11. Taylor et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. *J. Clin. Invest*. 2018 Aug 31;128(9):3819-3825. PMID: 29920189
12. Bejar et al. Clinical effect of point mutations in myelodysplastic syndromes. *N. Engl. J. Med*. 2011 Jun 30;364(26):2496-506. PMID: 21714648
13. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet*. 2013 Oct;45(10):1113-20. PMID: 24071849
14. NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 1.2021]
15. Curtis et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. *Br. J. Haematol*. 2007 Jul;138(1):77-81. PMID: 17555450
16. Curtis et al. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. *Leukemia*. 2007 Aug;21(8):1839-41. Epub 2007 May 17. PMID: 17508004
17. Gancheva et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. *Mol Cytogenet*. 2013 Sep 20;6(1):39. doi: 10.1186/1755-8166-6-39. PMID: 24053143
18. Drilon et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). *Ann Oncol*. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15. PMID: 26884591
19. Bibel et al. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. *Genes Dev*. 2000 Dec 1;14(23):2919-37. PMID: 11114882
20. Martin-Zanca et al. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. *Nature*. 1986 Feb 27-Mar 5;319(6056):743-8. PMID: 2869410
21. Amatu et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*. 2016 Mar 18;1(2):e000023. eCollection 2016. PMID: 27843590
22. Lange et al. Inhibiting TRK Proteins in Clinical Cancer Therapy. *Cancers (Basel)*. 2018 Apr 4;10(4). PMID: 29617282
23. Vaishnavi et al. TRKing down an old oncogene in a new era of targeted therapy. *Cancer Discov*. 2015 Jan;5(1):25-34. PMID: 25527197
24. Kim et al. NTRK1 fusion in glioblastoma multiforme. *PLoS ONE*. 2014;9(3):e91940. PMID: 24647444
25. Gatalica et al. Molecular characterization of cancers with NTRK gene fusions. *Mod. Pathol*. 2019 Jan;32(1):147-153. PMID: 30171197
26. Vaishnavi et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nat. Med*. 2013 Nov;19(11):1469-1472. PMID: 24162815
27. Rubin et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. *Am. J. Pathol*. 1998 Nov;153(5):1451-8. PMID: 9811336
28. Brzeźniańska et al. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. *Mutat. Res*. 2006 Jul 25;599(1-2):26-35. PMID: 16483615

References (continued)

29. Wu et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat. Genet.* 2014 May;46(5):444-450. PMID: 24705251
30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf
31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf
32. Fuse et al. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. *Mol. Cancer Ther.* 2017 Oct;16(10):2130-2143. PMID: 28751539
33. <https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-granted-fast-track-designation>